Technology
Our team applies deep expertise in biomaterials engineering, regenerative medicine, and ophthalmology to develop vision-restoring therapies that overcome the limitations of current cell therapy approaches.
Our next-generation hydrogel scaffold technology is engineered to improve the functional replacement and integration of therapeutic cells and the delivery of gene therapies. The technology protects cells during injection, localizes them to the target site, and provides a structure that promotes tissue regeneration while improving cell therapeutic function. The hydrogel is engineered to degrade naturally over time as it is replaced by the body’s newly formed tissue. The scaffold technology can also improve the delivery of therapeutics delivered to target sites in the body, such as the eye.
We believe our approach opens a new frontier for the development of treatments with the potential to restore vision in patients who currently have limited or no options.
OUR LEAD PROGRAM
GMX-101
The next generation of retinal pigment epithelial (RPE) cell therapy for treating geographic atrophy
GMX-101, uses induced pluripotent stem cell (iPSC)-derived retinal pigment epithelial (RPE) cells with the hydrogel technology to restore vision in late-stage GA, a leading cause of blindness in older adults.
In multiple preclinical studies, GMX-101 has demonstrated potential to overcome cell delivery challenges and regenerate the retina by improving cell survival and engraftment, leading to significant vision preservation while also eliminating the risks associated with other RPE cell therapies.
